Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.

Oncotarget · 2016 · PMC5342487 · PMID 26416414

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

a negative trendP = 0.063so close (0.05 < p ≤ 0.1)

A negative trend was also recorded in terms of OS (54 -95%CI 21.0- 73.3- vs 71 -95%CI 45.3- 82. 8- months, ( P = 0.063) respectively).

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.